Recent Updates
Recently added Catalysts
BMRN

BioMarin to Participate in Two Upcoming Virtual Investor Conferences BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D.,...

Key Takeaway: SAN RAFAEL, Calif. , June 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs , M.D., President, Worldwide Research & Development; and Brian Mueller , Acting Chief Finan

Full Press Release Details

SAN RAFAEL, Calif. , June 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs , M.D., President, Worldwide Research & Development; and Brian Mueller , Acting Chief Financial Officer, will participate in the Jefferies Virtual Healthcare Conference on June 4, 2020 at 4:00pm ET and the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020 at 2:10pm ET . An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
Contacts:
Investors Media
Traci McCarty Debra Charlesworth
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (415) 455-7451
SOURCE BioMarin Pharmaceutical Inc.

Related Links

21 %

Last updated: Jun 3, 2020